This trial will study whether a new drug, ravulizumab, is effective and safe for treating a condition called HSCT-TMA. The trial will have two stages: in the first stage, participants will receive the drug to see what dose works best; in the second stage, participants will be randomly assigned to receive either the drug or a placebo, and the effects of the drug will be compared to the placebo. The trial will last for 52 weeks total, with 26 weeks of treatment and 26 weeks of follow-up.
1 Primary · 8 Secondary · Reporting Duration: During the Follow-up Period (183-365 Days after start of study medication)
184 Total Participants · 2 Treatment Groups
Primary Treatment: Ravulizumab · Has Placebo Group · Phase 3
Age Any Age · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: